Novartis/Amgen End CNP520 Studies, Leaving Eisai/Biogen With Last BACE Inhibitor In The Clinic

 
• By Mandy Jackson
Alzheimers_677117191_Atthapon-Raksthaput_1200.jpg
Novartis and Amgen ended Phase II/III studies for BACE inhibitor CNP520. • Source: Shutterstock

More from Clinical Trials

More from R&D